SCHEMBL828065

SCHEMBL828065

CCC(=O)NC1CCCC1O

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 5/20 0.41
CNR1 P21554 3/20 0.41
CNR2 P34972 3/20 0.41
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TAS1R2 Q8TE23 1/20 0.38
ALDH1A1 P00352 1/20 0.37
USP2 O75604 1/20 0.37
JAK2 O60674 1/20 0.36
MITF O75030 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
HPGD P15428 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.35
PYGB P11216 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25069844 1.00 TRPV1 (0.41) TRPV1CNR1CNR2TAS1R3TAS1R1
SCHEMBL20942603 1.00 TRPV1 (0.41) TRPV1CNR1CNR2TAS1R3TAS1R1
SCHEMBL18361602 0.96 TRPV1 (0.41) TRPV1CNR1CNR2ALDH1A1USP2
SCHEMBL21258467 0.88 TRPV1 (0.43) TRPV1CNR1CNR2MTNR1AMTNR1B
SCHEMBL24022485 0.88 TRPV1 (0.43) TRPV1CNR1CNR2MTNR1AMTNR1B
SCHEMBL22858805 0.85 TRPV1 (0.50) TRPV1CNR1CNR2MTNR1AMTNR1B
SCHEMBL22859155 0.85 TRPV1 (0.50) TRPV1CNR1CNR2MTNR1AMTNR1B
SCHEMBL4342108 0.85 TRPV1 (0.50) TRPV1CNR1CNR2MTNR1AMTNR1B
SCHEMBL5021846 0.83 USP2 (0.44) TAS1R3TAS1R1TAS1R2ALDH1A1USP2
SCHEMBL22858735 0.81 TRPV1 (0.50) TRPV1CNR1CNR2SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019047915-A1 IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS BEIGENE, LTD. (KY) 2019-03-14 WO disclosed
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 US disclosed
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES CHRNA1, CHRNA5, CHRNA3 TRPV1 106/4885CNR1 56/4885CNR2 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.